BR0014814A - Método para alterar a expressão de uma seq ência alvo de ácido nucléico endógeno em uma célula alvo, transcrição de cdna e célula alvo - Google Patents

Método para alterar a expressão de uma seq ência alvo de ácido nucléico endógeno em uma célula alvo, transcrição de cdna e célula alvo

Info

Publication number
BR0014814A
BR0014814A BR0014814-8A BR0014814A BR0014814A BR 0014814 A BR0014814 A BR 0014814A BR 0014814 A BR0014814 A BR 0014814A BR 0014814 A BR0014814 A BR 0014814A
Authority
BR
Brazil
Prior art keywords
sequence
target cell
cdna
target
expression
Prior art date
Application number
BR0014814-8A
Other languages
English (en)
Inventor
Charles A Conrad
Original Assignee
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogenix Inc filed Critical Cytogenix Inc
Publication of BR0014814A publication Critical patent/BR0014814A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

"MéTODO PARA ALTERAR A EXPRESSãO DE UMA SEQ êNCIA ALVO DE áCIDO NUCLéICO ENDóGENO EM UMA CéLULA ALVO, TRANSCRIçãO DE CDNA E CéLULA ALVO". A presente invenção se refere a métodos para alterar a expressão de uma sequência alvo de ácido nucléico em uma célula alvo pela produção de cDNA(ss-cDNA) de cordão único na célula alvo in vivo. A célula alvo é transfectada com um cassete compreendendo uma seq³ência de interesse, uma repetição conjugada invertida e um local de ligação prímero 3' (PBS) para a repetição conjugada invertida. A transcrição do cassete pela célula alvo produz um templato RNA o qual é reversamente transcrito para produzir ss-cDNA de uma seq³ência específica. O gene de codificação transcriptase reversa/RNase também pode ser transfectado para a interior da célula de alvo. O ss-cDNA é modificado para remover todos os vetores de flanqueamento pelo tirar proveito da estrutura de enlace do ss-cDNA, a qual se forma como um resultado da repetição conjugada invertida que permite ao ss-cDNA dobrar-se sobre si mesmo, formando um cadeia de DNA de cordão duplo. A cadeia de cordão duplo contem um ou mais locais de restrição de reconhecimento de endonuclease e o enlace, o qual permanece como ssDNA, é compreendido da seq³ência de interesse, a qual pode ser qualquer seq³ência de nucleotídeos desejada. Este desenho permite à cadeia de cordão duplo do enlace de cadeia intermediário ser clivada pela(s) restrição(ões) de endonuclease correspondente(s) desejada(s) e a porção de enlace da seq³ência de interesse é então liberada como uma peça de DNA de cordão único, linearizada. Esta peça de ssDNA liberada (ou clivada) contem uma informação de seq³ência mínima, se ainda houver, seja a montante de 5' ou à jusante de 3' a partir da cadeia de cordão duplo. O ssDNA resultante se liga a uma seq³ência alvo de ácido nucléico endógeno para alterar a expressão daquela seq³ência para finalidades terapêuticas tais como a desativação de um gene usando uma ligação dupla ou tripla de ácidos nucléicos mutagenesis direcionados por local, a interrupção da função celular pela ligação a proteínas celulares específicas, e interferir com as funções de divisão de RNA.
BR0014814-8A 1999-10-04 2000-10-04 Método para alterar a expressão de uma seq ência alvo de ácido nucléico endógeno em uma célula alvo, transcrição de cdna e célula alvo BR0014814A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41156899A 1999-10-04 1999-10-04
US51470700A 2000-02-28 2000-02-28
PCT/US2000/027381 WO2001025419A1 (en) 1999-10-04 2000-10-04 ALTERING GENE EXPRESSION WITH ssDNA PRODUCED IN VIVO

Publications (1)

Publication Number Publication Date
BR0014814A true BR0014814A (pt) 2002-09-17

Family

ID=27021437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014814-8A BR0014814A (pt) 1999-10-04 2000-10-04 Método para alterar a expressão de uma seq ência alvo de ácido nucléico endógeno em uma célula alvo, transcrição de cdna e célula alvo

Country Status (11)

Country Link
EP (1) EP1222259A1 (pt)
JP (1) JP2003511025A (pt)
KR (1) KR20020059608A (pt)
CN (1) CN1276083C (pt)
AU (1) AU7855300A (pt)
BR (1) BR0014814A (pt)
CA (1) CA2386246A1 (pt)
CR (1) CR6613A (pt)
IL (1) IL148946A0 (pt)
MX (1) MXPA02003422A (pt)
WO (1) WO2001025419A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419964B2 (en) 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
ATE386821T1 (de) 2000-10-23 2008-03-15 Gen Probe Inc Zusammensetzungen und methoden zur detektion von humanem immundefizienz virus 2 (hiv-2)
EP1468086A2 (en) * 2001-12-14 2004-10-20 Yale University INTRACELLULAR GENERATION OF SINGLE−STRANDED DNA
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
KR20070074574A (ko) * 2004-09-28 2007-07-12 사이토제닉, 인크. 단일-가닥 항균성 올리고뉴클레오티드 및 그의 사용
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CN102154269B (zh) * 2011-01-06 2012-05-23 湖南农业大学 基于pcr的串联重复序列快速构建法和专用引物对及应用
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CN108396043A (zh) * 2017-02-06 2018-08-14 中国科学院上海应用物理研究所 一种5`端磷酸化单链dna的制备方法及其应用
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
JP7481755B2 (ja) * 2018-11-02 2024-05-13 ナイキジェン，リミテッド 組換えパルボウイルスベクターならびにその作製および使用方法
GB201913898D0 (en) * 2019-09-26 2019-11-13 Lightbio Ltd Nucleic acid construct
CN116286979A (zh) * 2023-03-07 2023-06-23 长沙忠健科技有限公司 一种表达逆转录酶和rna序列的质粒、细胞及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022114A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. PRODUCTION OF ssDNA $i(IN VIVO)
BR9914772A (pt) * 1998-10-09 2001-12-11 Ingene Inc Conjunto de elementos genéticos, vetor, célulahospedeira, conjunto para a produção de umasequência de ácido nucléico, método para aprodução in vivo ou in vitro de uma sequência deácido nucléico, transcrição de cdna, molécula deácido nucléico inibidor, transcrição de mrna,molécula heteroduplex e composiçãofarmacêutica

Also Published As

Publication number Publication date
MXPA02003422A (es) 2004-09-10
WO2001025419A1 (en) 2001-04-12
CA2386246A1 (en) 2001-04-12
CR6613A (es) 2004-04-21
JP2003511025A (ja) 2003-03-25
AU7855300A (en) 2001-05-10
CN1399679A (zh) 2003-02-26
CN1276083C (zh) 2006-09-20
EP1222259A1 (en) 2002-07-17
IL148946A0 (en) 2002-09-12
KR20020059608A (ko) 2002-07-13

Similar Documents

Publication Publication Date Title
BR9914773A (pt) Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica
Gooding et al. Smooth muscle‐specific switching of alpha‐tropomyosin mutually exclusive exon selection by specific inhibition of the strong default exon.
AU2017242794B2 (en) Novel minimal UTR sequences
AU591104B2 (en) Process for amplifying, detecting, and/or cloning nucleic acid sequences
ATE251220T1 (de) Verfahen zur gleichzeitigen identifikation von differentielle exprimierten mrna's und zur messung ihrer relativen konzentration
EP1251179A3 (en) Method for protein expression starting from stabilized linear short DNA in cell-free in vitro transcription/translation systems with exonuclease-containing lysates or in a cellular system containing exonucleases
WO2002061034A3 (en) Compositions and methods for rapidly generating recombinant nucleic acid molecules
MXPA02003422A (es) Alteracion de la expresion de genes con adnss producido in vivo.
Piller et al. Resolution of the RNA editing gRNA-directed endonuclease from two other endonucleases of Trypanosoma brucei mitochondria.
EP1282684A4 (en) CHONDROITIN SYNTHASE GENES AND METHOD FOR THE PRODUCTION AND USE THEREOF
BR9809493A (pt) Modificação in vivo de galactomananas em guar por expressão de arn de anti-sentido de udp-galactose epimerase
KR20250122519A (ko) 자가환형화 rna의 제조 방법
DK0857220T3 (da) Sekvensmodifikation af oligonucleotidprimere til manipulering af ikke-templateret nucleotidaddition
Man-Young The Origin of Korean Music
Hastanto Tembang Macapat in Central Java
SE0003002D0 (sv) New sequences
Wright AP and ED
Struga How the Musicality of Ethnolinguistic Affects the Cognitive Abilities for Further Learning
Činč FOLK MUSIC CREATIVITY OF THE PEOPLE OF FORMER YUGOSLAVIA AS A FUNCTION OF THE OUTCOME OF MUSICAL EDUCATION
Böldicke et al. Rifampicin-resistant initiation of DNA synthesis on the isolated strands of CoIE plasmid DNA
Duran Is it okay to tell a dancer their arms look like a dead chicken?
Zubović Music of the Muslim People in Bosnia and Herzegovina at the Time of the Ottoman Administration-Musical Instruments
Miller Euripides and Eustathius
Lewis Child &
WO2002059608A3 (en) Compositions and methods related to chemokine (c motif) xc receptor 1 (ccxcr1)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.